ANGO

SEC source: 0001140361-26-030514 · form4.xml · nonDerivative · entry 1

Nighan Warren JR · CIK 0001507345 · SVP Quality and Regulatory

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 64,745

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $14.65 to $14.80, inclusive. The reporting person has provided to AngioDynamics, Inc., and undertakes to provide to any security holder of AngioDynamics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote 1.

SEC source: 0001140361-26-029636 · form4.xml · derivative · entry 3

Piccinini Laura · CIK 0001875140 · SVP International

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 28,336 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: On July 19, 2023, the reporting person received a target grant of 28,336 performance share units. Between 0% and 200% of the target number was to be earned based on achievement of pre-determined performance metrics for fiscal years 2024, 2025 and 2026 as determined by the compensation committee. In addition, 20% of the total shares earned could be awarded (or cancelled) based on total shareholder return relative to a peer group of companies over a three-year performance period in accordance with performance metrics. Based on performance over the period, 8,047 shares of Common Stock were issued to the reporting person under this grant and the remaining shares were forfeited.

F3 · derivative.exercise_date: On July 19, 2023, the reporting person received a target grant of 28,336 performance share units. Between 0% and 200% of the target number was to be earned based on achievement of pre-determined performance metrics for fiscal years 2024, 2025 and 2026 as determined by the compensation committee. In addition, 20% of the total shares earned could be awarded (or cancelled) based on total shareholder return relative to a peer group of companies over a three-year performance period in accordance with performance metrics. Based on performance over the period, 8,047 shares of Common Stock were issued to the reporting person under this grant and the remaining shares were forfeited.

F3 · derivative.expiration_date: On July 19, 2023, the reporting person received a target grant of 28,336 performance share units. Between 0% and 200% of the target number was to be earned based on achievement of pre-determined performance metrics for fiscal years 2024, 2025 and 2026 as determined by the compensation committee. In addition, 20% of the total shares earned could be awarded (or cancelled) based on total shareholder return relative to a peer group of companies over a three-year performance period in accordance with performance metrics. Based on performance over the period, 8,047 shares of Common Stock were issued to the reporting person under this grant and the remaining shares were forfeited.

SEC source: 0001140361-26-029636 · form4.xml · nonDerivative · entry 2

Piccinini Laura · CIK 0001875140 · SVP International

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 81,929

F2 · shares: The exempt disposition of 4,506 shares of Common Stock of AngioDynamics was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying performance share units granted to the reporting person on July 19, 2023.

SEC source: 0001140361-26-029636 · form4.xml · nonDerivative · entry 1

Piccinini Laura · CIK 0001875140 · SVP International

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 86,435

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: This acquisition of 8,047 shares of Common Stock ("Common Stock") of AngioDynamics, Inc. ("AngioDynamics") represents shares acquired through the vesting and settlement of performance share units granted to the reporting person on July 19, 2023.

SEC source: 0001140361-26-029633 · form4.xml · derivative · entry 3

Clemmer James C · CIK 0001476700 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 184,361 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: On July 19, 2023, the reporting person received a target grant of 184,361 performance share units. Between 0% and 200% of the target number was to be earned based on achievement of pre-determined performance metrics for fiscal years 2024, 2025 and 2026 as determined by the compensation committee. In addition, 20% of the total shares earned could be awarded (or cancelled) based on total shareholder return relative to a peer group of companies over a three-year performance period in accordance with performance metrics. Based on performance over the period, 52,358 shares of Common Stock were issued to the reporting person under this grant and the remaining shares were forfeited.

F3 · derivative.exercise_date: On July 19, 2023, the reporting person received a target grant of 184,361 performance share units. Between 0% and 200% of the target number was to be earned based on achievement of pre-determined performance metrics for fiscal years 2024, 2025 and 2026 as determined by the compensation committee. In addition, 20% of the total shares earned could be awarded (or cancelled) based on total shareholder return relative to a peer group of companies over a three-year performance period in accordance with performance metrics. Based on performance over the period, 52,358 shares of Common Stock were issued to the reporting person under this grant and the remaining shares were forfeited.

F3 · derivative.expiration_date: On July 19, 2023, the reporting person received a target grant of 184,361 performance share units. Between 0% and 200% of the target number was to be earned based on achievement of pre-determined performance metrics for fiscal years 2024, 2025 and 2026 as determined by the compensation committee. In addition, 20% of the total shares earned could be awarded (or cancelled) based on total shareholder return relative to a peer group of companies over a three-year performance period in accordance with performance metrics. Based on performance over the period, 52,358 shares of Common Stock were issued to the reporting person under this grant and the remaining shares were forfeited.

SEC source: 0001140361-26-029633 · form4.xml · nonDerivative · entry 2

Clemmer James C · CIK 0001476700 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 862,448

F2 · shares: The exempt disposition of 26,728 shares of Common Stock of AngioDynamics was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying performance share units granted to the reporting person on July 19, 2023.

SEC source: 0001140361-26-029633 · form4.xml · nonDerivative · entry 1

Clemmer James C · CIK 0001476700 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 889,176

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: This acquisition of 52,358 shares of Common Stock ("Common Stock") of AngioDynamics, Inc. ("AngioDynamics") represents shares acquired through the vesting and settlement of performance share units granted to the reporting person on July 19, 2023.

SEC source: 0001140361-26-029635 · form4.xml · derivative · entry 3

Nighan Warren JR · CIK 0001507345 · SVP Quality and Regulatory

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 20,052 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: On July 19, 2023, the reporting person received a target grant of 20,052 performance share units. Between 0% and 200% of the target number was to be earned based on achievement of pre-determined performance metrics for fiscal years 2024, 2025 and 2026 as determined by the compensation committee. In addition, 20% of the total shares earned could be awarded (or cancelled) based on total shareholder return relative to a peer group of companies over a three-year performance period in accordance with performance metrics. Based on performance over the period, 5,694 shares of Common Stock were issued to the reporting person under this grant and the remaining shares were forfeited.

F3 · derivative.exercise_date: On July 19, 2023, the reporting person received a target grant of 20,052 performance share units. Between 0% and 200% of the target number was to be earned based on achievement of pre-determined performance metrics for fiscal years 2024, 2025 and 2026 as determined by the compensation committee. In addition, 20% of the total shares earned could be awarded (or cancelled) based on total shareholder return relative to a peer group of companies over a three-year performance period in accordance with performance metrics. Based on performance over the period, 5,694 shares of Common Stock were issued to the reporting person under this grant and the remaining shares were forfeited.

F3 · derivative.expiration_date: On July 19, 2023, the reporting person received a target grant of 20,052 performance share units. Between 0% and 200% of the target number was to be earned based on achievement of pre-determined performance metrics for fiscal years 2024, 2025 and 2026 as determined by the compensation committee. In addition, 20% of the total shares earned could be awarded (or cancelled) based on total shareholder return relative to a peer group of companies over a three-year performance period in accordance with performance metrics. Based on performance over the period, 5,694 shares of Common Stock were issued to the reporting person under this grant and the remaining shares were forfeited.

SEC source: 0001140361-26-029635 · form4.xml · nonDerivative · entry 2

Nighan Warren JR · CIK 0001507345 · SVP Quality and Regulatory

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 88,115

F2 · shares: The exempt disposition of 1,671 shares of Common Stock of AngioDynamics was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying performance share units granted to the reporting person on July 19, 2023.

SEC source: 0001140361-26-029635 · form4.xml · nonDerivative · entry 1

Nighan Warren JR · CIK 0001507345 · SVP Quality and Regulatory

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 89,786

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: This acquisition of 5,694 shares of Common Stock ("Common Stock") of AngioDynamics, Inc. ("AngioDynamics") represents shares acquired through the vesting and settlement of performance share units granted to the reporting person on July 19, 2023.

SEC source: 0001140361-26-029634 · form4.xml · derivative · entry 3

Trowbridge Stephen A · CIK 0001624250 · EVP and CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 57,381 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: On July 19, 2023, the reporting person received a target grant of 57,381 performance share units. Between 0% and 200% of the target number was to be earned based on achievement of pre-determined performance metrics for fiscal years 2024, 2025 and 2026 as determined by the compensation committee. In addition, 20% of the total shares earned could be awarded (or cancelled) based on total shareholder return relative to a peer group of companies over a three-year performance period in accordance with performance metrics. Based on performance over the period, 16,296 shares of Common Stock were issued to the reporting person under this grant and the remaining shares were forfeited.

F3 · derivative.exercise_date: On July 19, 2023, the reporting person received a target grant of 57,381 performance share units. Between 0% and 200% of the target number was to be earned based on achievement of pre-determined performance metrics for fiscal years 2024, 2025 and 2026 as determined by the compensation committee. In addition, 20% of the total shares earned could be awarded (or cancelled) based on total shareholder return relative to a peer group of companies over a three-year performance period in accordance with performance metrics. Based on performance over the period, 16,296 shares of Common Stock were issued to the reporting person under this grant and the remaining shares were forfeited.

F3 · derivative.expiration_date: On July 19, 2023, the reporting person received a target grant of 57,381 performance share units. Between 0% and 200% of the target number was to be earned based on achievement of pre-determined performance metrics for fiscal years 2024, 2025 and 2026 as determined by the compensation committee. In addition, 20% of the total shares earned could be awarded (or cancelled) based on total shareholder return relative to a peer group of companies over a three-year performance period in accordance with performance metrics. Based on performance over the period, 16,296 shares of Common Stock were issued to the reporting person under this grant and the remaining shares were forfeited.

SEC source: 0001140361-26-029634 · form4.xml · nonDerivative · entry 2

Trowbridge Stephen A · CIK 0001624250 · EVP and CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 305,796

F2 · shares: The exempt disposition of 8,319 shares of Common Stock of AngioDynamics was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying performance share units granted to the reporting person on July 19, 2023.

SEC source: 0001140361-26-029634 · form4.xml · nonDerivative · entry 1

Trowbridge Stephen A · CIK 0001624250 · EVP and CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 314,115

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: This acquisition of 16,296 shares of Common Stock ("Common Stock") of AngioDynamics, Inc. ("AngioDynamics") represents shares acquired through the vesting and settlement of performance share units granted to the reporting person on July 19, 2023.

SEC source: 0001140361-26-029632 · form4.xml · derivative · entry 3

Campbell Chad Thomas · CIK 0001706852 · SVP/GM, Vascular Access

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 22,768 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: On July 19, 2023, the reporting person received a target grant of 22,768 performance share units. Between 0% and 200% of the target number was to be earned based on achievement of pre-determined performance metrics for fiscal years 2024, 2025 and 2026 as determined by the compensation committee. In addition, 20% of the total shares earned could be awarded (or cancelled) based on total shareholder return relative to a peer group of companies over a three-year performance period in accordance with performance metrics. Based on performance over the period, 6,466 shares of Common Stock were issued to the reporting person under this grant and the remaining shares were forfeited.

F3 · derivative.exercise_date: On July 19, 2023, the reporting person received a target grant of 22,768 performance share units. Between 0% and 200% of the target number was to be earned based on achievement of pre-determined performance metrics for fiscal years 2024, 2025 and 2026 as determined by the compensation committee. In addition, 20% of the total shares earned could be awarded (or cancelled) based on total shareholder return relative to a peer group of companies over a three-year performance period in accordance with performance metrics. Based on performance over the period, 6,466 shares of Common Stock were issued to the reporting person under this grant and the remaining shares were forfeited.

F3 · derivative.expiration_date: On July 19, 2023, the reporting person received a target grant of 22,768 performance share units. Between 0% and 200% of the target number was to be earned based on achievement of pre-determined performance metrics for fiscal years 2024, 2025 and 2026 as determined by the compensation committee. In addition, 20% of the total shares earned could be awarded (or cancelled) based on total shareholder return relative to a peer group of companies over a three-year performance period in accordance with performance metrics. Based on performance over the period, 6,466 shares of Common Stock were issued to the reporting person under this grant and the remaining shares were forfeited.

SEC source: 0001140361-26-029632 · form4.xml · nonDerivative · entry 2

Campbell Chad Thomas · CIK 0001706852 · SVP/GM, Vascular Access

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 108,676

F2 · shares: The exempt disposition of 2,330 shares of Common Stock of AngioDynamics was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying performance share units granted to the reporting person on July 19, 2023.

SEC source: 0001140361-26-029632 · form4.xml · nonDerivative · entry 1

Campbell Chad Thomas · CIK 0001706852 · SVP/GM, Vascular Access

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 111,006

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: This acquisition of 6,466 shares of Common Stock ("Common Stock") of AngioDynamics, Inc. ("AngioDynamics") represents shares acquired through the vesting and settlement of performance share units granted to the reporting person on July 19, 2023.

SEC source: 0001140361-26-029185 · form4.xml · nonDerivative · entry 3

Piccinini Laura · CIK 0001875140 · SVP International

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 58,528

F3 · shares: The exempt disposition of 616 shares of common stock of AngioDynamics was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 20, 2022.

SEC source: 0001140361-26-029178 · form4.xml · nonDerivative · entry 5

Clemmer James C · CIK 0001476700 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 836,818

F5 · shares: The exempt disposition of 4,223 shares of common stock of AngioDynamics was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 20, 2022.

SEC source: 0001140361-26-029188 · form4.xml · nonDerivative · entry 3

Trowbridge Stephen A · CIK 0001624250 · EVP and CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 244,562

F3 · shares: The exempt disposition of 717 shares of common stock of AngioDynamics was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 20, 2022.

SEC source: 0001140361-26-029181 · form4.xml · nonDerivative · entry 3

Nighan Warren JR · CIK 0001507345 · SVP Quality and Regulatory

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 66,126

F3 · shares: The exempt disposition of 251 shares of common stock of AngioDynamics was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 20, 2022.

SEC source: 0001140361-26-029176 · form4.xml · nonDerivative · entry 3

Campbell Chad Thomas · CIK 0001706852 · SVP/GM, Vascular Access

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 88,459

F3 · shares: The exempt disposition of 359 shares of common stock of AngioDynamics was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 20, 2022.

SEC source: 0001140361-26-029178 · form4.xml · nonDerivative · entry 4

Clemmer James C · CIK 0001476700 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 841,041

F4 · shares: The exempt disposition of 487 shares of common stock of AngioDynamics was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 19, 2024.

SEC source: 0001140361-26-029178 · form4.xml · nonDerivative · entry 3

Clemmer James C · CIK 0001476700 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 841,528

F3 · shares: The exempt disposition of 11,764 shares of common stock of AngioDynamics was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 19, 2023.

SEC source: 0001140361-26-029185 · form4.xml · nonDerivative · entry 2

Piccinini Laura · CIK 0001875140 · SVP International

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 59,144

F2 · shares: The exempt disposition of 3,074 shares of common stock of AngioDynamics was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 17, 2024.

SEC source: 0001140361-26-029178 · form4.xml · nonDerivative · entry 2

Clemmer James C · CIK 0001476700 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 853,292

F2 · shares: The exempt disposition of 10,649 shares of common stock of AngioDynamics was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 17, 2024.

SEC source: 0001140361-26-029188 · form4.xml · nonDerivative · entry 2

Trowbridge Stephen A · CIK 0001624250 · EVP and CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 245,279

F2 · shares: The exempt disposition of 3,510 shares of common stock of AngioDynamics was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 17, 2024.

SEC source: 0001140361-26-029181 · form4.xml · nonDerivative · entry 2

Nighan Warren JR · CIK 0001507345 · SVP Quality and Regulatory

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 66,377

F2 · shares: The exempt disposition of 1,373 shares of common stock of AngioDynamics was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 17, 2024.

SEC source: 0001140361-26-029176 · form4.xml · nonDerivative · entry 2

Campbell Chad Thomas · CIK 0001706852 · SVP/GM, Vascular Access

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 88,818

F2 · shares: The exempt disposition of 1,112 shares of common stock of AngioDynamics was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 17, 2024.

SEC source: 0001140361-26-029185 · form4.xml · nonDerivative · entry 1

Piccinini Laura · CIK 0001875140 · SVP International

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 62,218

F1 · shares: The exempt disposition of 4,538 shares of common stock of AngioDynamics, Inc. ("AngioDynamics") was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 16, 2025.

SEC source: 0001140361-26-029178 · form4.xml · nonDerivative · entry 1

Clemmer James C · CIK 0001476700 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 863,941

F1 · shares: The exempt disposition of 18,588 shares of common stock of AngioDynamics, Inc. ("AngioDynamics") was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 16, 2025.

SEC source: 0001140361-26-029190 · form4.xml · nonDerivative · entry 1

Weiss Lawrence T · CIK 0001930293 · SVP, Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 91,330

F1 · shares: The exempt disposition of 2,267 shares of common stock of AngioDynamics, Inc. was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 16, 2025.

SEC source: 0001140361-26-029188 · form4.xml · nonDerivative · entry 1

Trowbridge Stephen A · CIK 0001624250 · EVP and CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 248,789

F1 · shares: The exempt disposition of 7,840 shares of common stock of AngioDynamics, Inc. ("AngioDynamics") was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 16, 2025.

SEC source: 0001140361-26-029181 · form4.xml · nonDerivative · entry 1

Nighan Warren JR · CIK 0001507345 · SVP Quality and Regulatory

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 67,750

F1 · shares: The exempt disposition of 2,153 shares of common stock of AngioDynamics, Inc. ("AngioDynamics") was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 16, 2025.

SEC source: 0001140361-26-029176 · form4.xml · nonDerivative · entry 1

Campbell Chad Thomas · CIK 0001706852 · SVP/GM, Vascular Access

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 89,930

F1 · shares: The exempt disposition of 2,367 shares of common stock of AngioDynamics, Inc. ("AngioDynamics") was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 16, 2025.

SEC source: 0001140361-26-029341 · form4.xml · nonDerivative · entry 1

REED JAN STERN · CIK 0001124181 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 116,921

F1 · shares: The acquisition of 11,887 shares of common stock of AngioDynamics, Inc. ("AngioDynamics") represents 11,887 restricted stock units granted as regular annual compensation for service as a director of AngioDynamics. The restricted stock units immediately vested at the time of grant.

SEC source: 0001140361-26-029333 · form4.xml · derivative · entry 2

Piccinini Laura · CIK 0001875140 · SVP International

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,860

Underlying: Common Stock · 19,860 shares

Expires not disclosed

F2 · derivative.exercise_price: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period (with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate)) in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited.

F2 · derivative.exercise_date: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period (with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate)) in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited.

F2 · derivative.expiration_date: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period (with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate)) in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited.

SEC source: 0001140361-26-029333 · form4.xml · nonDerivative · entry 1

Piccinini Laura · CIK 0001875140 · SVP International

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 78,388

F1 · shares: The acquisition of 19,860 shares of common stock ("Common Stock") of AngioDynamics, Inc. represents 19,860 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. These restricted stock units vest in four equal annual installments beginning on July 15, 2027, such that 25% of the restricted stock units will vest on each of July 15, 2027, 2028, 2029 and 2030.

SEC source: 0001140361-26-029336 · form4.xml · nonDerivative · entry 1

Auen Eileen O'Shea · CIK 0001428073 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 116,605

F1 · shares: The acquisition of 11,887 shares of common stock of AngioDynamics, Inc. ("AngioDynamics") represents 11,887 restricted stock units granted as regular annual compensation for service as a director of AngioDynamics. The restricted stock units immediately vested at the time of grant.

SEC source: 0001140361-26-029339 · form4.xml · nonDerivative · entry 1

JOHNSON WESLEY · CIK 0001258791 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 155,425

F1 · shares: The acquisition of 11,887 shares of common stock of AngioDynamics, Inc. ("AngioDynamics") represents 11,887 restricted stock units granted as regular annual compensation for service as a director of AngioDynamics. The restricted stock units immediately vested at the time of grant.

SEC source: 0001140361-26-029338 · form4.xml · nonDerivative · entry 1

DONNELLY HOWARD W · CIK 0001212978 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 178,938

F1 · shares: The acquisition of 11,887 shares of common stock of AngioDynamics, Inc. ("AngioDynamics") represents 11,887 restricted stock units granted as regular annual compensation for service as a director of AngioDynamics. The restricted stock units immediately vested at the time of grant.

SEC source: 0001140361-26-029340 · form4.xml · nonDerivative · entry 1

Licitra Karen A · CIK 0001754757 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 102,322

F1 · shares: The acquisition of 11,887 shares of common stock of AngioDynamics, Inc. ("AngioDynamics") represents 11,887 restricted stock units granted as regular annual compensation for service as a director of AngioDynamics. The restricted stock units immediately vested at the time of grant.

SEC source: 0001140361-26-029337 · form4.xml · nonDerivative · entry 1

Burgess Lorinda · CIK 0001843912 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 67,144

F1 · shares: The acquisition of 11,887 shares of common stock of AngioDynamics, Inc. ("AngioDynamics") represents 11,887 restricted stock units granted as regular annual compensation for service as a director of AngioDynamics. The restricted stock units immediately vested at the time of grant.

SEC source: 0001140361-26-029335 · form4.xml · nonDerivative · entry 1

Tarnoff Michael E · CIK 0001603289 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 95,265

F1 · shares: The acquisition of 11,887 shares of common stock of AngioDynamics, Inc. ("AngioDynamics") represents 11,887 restricted stock units granted as regular annual compensation for service as a director of AngioDynamics. The restricted stock units immediately vested at the time of grant.

SEC source: 0001140361-26-029334 · form4.xml · derivative · entry 2

Trowbridge Stephen A · CIK 0001624250 · EVP and CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 53,257

Underlying: Common Stock · 53,257 shares

Expires not disclosed

F2 · derivative.exercise_price: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period (with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate)) in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited.

F2 · derivative.exercise_date: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period (with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate)) in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited.

F2 · derivative.expiration_date: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period (with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate)) in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited.

SEC source: 0001140361-26-029334 · form4.xml · nonDerivative · entry 1

Trowbridge Stephen A · CIK 0001624250 · EVP and CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 297,819

F1 · shares: The acquisition of 53,257 shares of common stock ("Common Stock") of AngioDynamics, Inc. represents 53,257 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. These restricted stock units vest in four equal annual installments beginning on July 15, 2027, such that 25% of the restricted stock units will vest on each of July 15, 2027, 2028, 2029 and 2030.

SEC source: 0001140361-26-029332 · form4.xml · derivative · entry 2

Nighan Warren JR · CIK 0001507345 · SVP Quality and Regulatory

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,966

Underlying: Common Stock · 17,966 shares

Expires not disclosed

F2 · derivative.exercise_price: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period (with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate)) in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited.

F2 · derivative.exercise_date: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period (with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate)) in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited.

F2 · derivative.expiration_date: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period (with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate)) in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited.

SEC source: 0001140361-26-029332 · form4.xml · nonDerivative · entry 1

Nighan Warren JR · CIK 0001507345 · SVP Quality and Regulatory

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 84,092

F1 · shares: The acquisition of 17,966 shares of common stock ("Common Stock") of AngioDynamics, Inc. represents 17,966 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. These restricted stock units vest in four equal annual installments beginning on July 15, 2027, such that 25% of the restricted stock units will vest on each of July 15, 2027, 2028, 2029 and 2030.

SEC source: 0001140361-26-029331 · form4.xml · derivative · entry 2

Campbell Chad Thomas · CIK 0001706852 · SVP/GM, Vascular Access

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,081

Underlying: Common Stock · 16,081 shares

Expires not disclosed

F2 · derivative.exercise_price: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period (with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate)) in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited.

F2 · derivative.exercise_date: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period (with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate)) in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited.

F2 · derivative.expiration_date: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period (with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate)) in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited.

SEC source: 0001140361-26-029331 · form4.xml · nonDerivative · entry 1

Campbell Chad Thomas · CIK 0001706852 · SVP/GM, Vascular Access

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 104,540

F1 · shares: The acquisition of 16,081 shares of common stock ("Common Stock") of AngioDynamics, Inc. represents 16,081 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. These restricted stock units vest in four equal annual installments beginning on July 15, 2027, such that 25% of the restricted stock units will vest on each of July 15, 2027, 2028, 2029 and 2030.

SEC source: 0001140361-26-029330 · form4.xml · derivative · entry 2

Weiss Lawrence T · CIK 0001930293 · SVP, Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,288

Underlying: Common Stock · 21,288 shares

Expires not disclosed

F2 · derivative.exercise_price: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period (with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate)) in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited.

F2 · derivative.exercise_date: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period (with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate)) in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited.

F2 · derivative.expiration_date: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period (with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate)) in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited.